Posted by Michael Wonder on 27 Jan 2023
Dupixent (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
27 January 2023 - Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life.
The EMA’s CHMP adopted a positive opinion for Dupixent (dupilumab), recommending expanded approval in the European Union to treat severe atopic dermatitis in children 6 months to 5 years old who are candidates for systemic therapy.
